The U.S. Federal Trade Commission said yesterday that it cleared Fresenius (NYSE:FMS) in its $2 billion acquisition of NxStage Medical (NSDQ:NXTM). As part of the approval, NxStage will have to part ways with its bloodline tubing set business, offloading them to B. Braun, according to the regulatory agency. The vote to approve the merger was split, however, […]
Fresenius launches 2008T BlueStar hemodialysis machine in U.S.
Fresenius Medical Care (NYSE:FMS) said today that it launched its 2008T BlueStar hemodialysis machine, touting more than 30 improvements from previous device models. The Waltham, Mass.-based company said that the new system is intended to allow for simpler operation and maintenance with additional treatment options, and added that the system features a number of newly automated technologies. […]
U.S. gov’t shutdown again delays closing for Fresenius-NxStage merger
Fresenius (NYSE:FMS) said today that an interruption to the FTC’s review of its merger with NxStage Medical (NSDQ:NXTM), caused by the partial U.S. government shutdown, has again delayed the end-date of the deal which has now been extended to August 6, 2019. The end-date is not hard-set, Fresenius said, and could occur on an earlier date if there have […]
Fresenius still awaiting FTC approval for NxStage acquisition
Fresenius (NYSE:FMS) said last Friday that it is still in the process of seeking approval from the U.S. Federal Trade Commission for its $2 billion merger with NxStage Medical (NSDQ:NXTM). The tie-up, which was delayed by NxStage in October in light of the FTC investigation, has been in the works for nearly a year and a half, having […]
Del. supremes uphold Fresenius bailout on Akorn buy
Delaware’s Supreme Court ruled last week to uphold a decision by the state’s Chancery Court that Fresenius (ETR:FRE) could walk away from its $4 billion merger with Akorn (NSDQ:AKRX). The initial deal was designed to help Fresenius move into new therapeutic areas and dosage forms, including eye drugs, ear drops, nasal sprays and respiratory drugs. But Fresenius abandoned the purchase in […]
Fresenius slides on softened outlook
Fresenius (NYSE:FMS) shares are down roughly 10% today after the German dialysis giant softened its outlook. “Given its current expectations for 2018 and 2019, Fresenius now believes its ambitious group targets for 2020 will not be met,” Fresenius said. Overall earnings next year are now expected to be flat on mid-single-digit sales growth, compared with prior […]
Fresenius Kabi recalls sodium chloride injections over latex concern
Fresenius Kabi USA voluntarily recalled 163 lots of sodium chloride injections last week, noting that the product contains latex despite an insert that states otherwise. The company’s recall includes 0.9% injections in 10 mL vials and 20 mL vials. The product insert and the tray label for both kinds of vials say that the products’ stoppers […]
Fresenius posts shrinking sales, profits in Q3
Fresenius (NYSE:FMS) shares have stayed steady today after the company released third quarter earnings that saw profits and sales shrink compared to the previous year. The Bad Homburg, Germany-based company posted profits of $322.6 million (EU €285 million), or $1.05 per share (EU €0.93), on sales of approximately $4.6 billion (EU €4.1 billion) for the three […]
NxStage Medical, Fresenius again delay $2B merger
NxStage Medical (NSDQ:NXTM) yesterday once more delayed its pending $2 billion merger with Fresenius (NYSE:FMS) as the U.S. Federal Trade Commission continues to examine the deal. In July, the German renal care giant and Lawrence, Mass.-based NxStage extended the deal’s closing date by 90 days, from August 7 to Nov. 5, saying it still expected to close the deal this year. […]
Fresenius Medical touts Crit-Line hemodialysis fluid management studies
Fresenius Medical Care‘s (NYSE:FMS) renal therapies group today released results from four studies of its Crit-Line monitor that looked to explore the relation between relative blood volume monitoring (RBV-M) and patient outcomes. Data from the studies were presented at the 2018 American Society of Nephrology’s Kidney Week Symposium in San Diego, Calif. Results from two […]
Fresenius plunges on missed prelims, guidance cut
Fresenius (NYSE:FMS) shares closed down some 17% yesterday after it cut its outlook for the rest of the year on lower-than-expected third-quarter results. The German dialysis giant released preliminary figures for the three months ended Sept. 30, saying it expects to report profits of €285 million on sales of €4.06 billion. Analysts were looking for sales of €4.12 billion. […]
- 1
- 2
- 3
- …
- 12
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube